Endocrinology
doi: 10.25005/2074-0581-2022-24-4-562-568
AUTOIMMUNE POLYGLANDULAR SYNDROME PREVALENCE IN TOLUCA, MEXICO

Concepción Carrillo LE1, Rodríguez Piña MD1, Pineda González MG1, García Ocampo F1, Mendieta Zerón H1,2

1Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, Mexico
2Maternal-Perinatal Hospital «Mónica Pretelini Sáenz», Toluca, Mexico

Objective: Autoimmune polyglandular syndromes (APS) are endocrinopathies whose main characteristic is the loss of immune tolerance. The objective of this work was to report the APS prevalence in an Internal Medicine Service from Toluca, Mexico.

Methods: This was a descriptive and retrospective study. Medical files from the service of Internal Medicine at Ciprés Grupo Médico CGM SC (CGM), Toluca, Mexico, in a period of 11 years were analyzed. The prevalence of APS was obtained taking into account all the patients seen in the mentioned period and in particular considering only the following diseases: diabetes mellitus, thyroiditis and Addison's disease.

Results: From 2000 clinical files, five cases (0.25%) are presented according to the criteria and clinical manifestations. APS detection among patients who were treated for endocrine pathology (diabetes mellitus = 807, thyroiditis = 473, and hypocortisolism = 5) were 5 in 1285 (0.38%).

Conclusion: APS-2 is the most common type of APS in a common Internal Medicine service in Toluca, Mexico.

Keywords: Autoimmune polyglandular syndrome, hypothyroidism, type 1 diabetes mellitus.

Download file:

References
  1. Letelier BMC. Síndromes endocrinos autoinmunes: cuándo sospechar y estudiar un síndrome poliglandular (SPG). Rev Med Clin Conde. 2013;24(5):784-9.
  2. Husebye ES, Anderson MS, Kämpe O. Autoimmune polyendocrine syndromes. N Engl J Med. 2018;378(12):1132-41
  3. Zirilli G, Santucci S, Cuzzupè C, Corica D, Pitrolo E, Salzano G. Peculiarities of autoimmune polyglandular syndromes in children and adolescents. Acta Biomed. 2017;88(3):271-5.
  4. Neufeld M, Maclaren N, Blizzard R. Autoimmune polyglandular syndromes. Pediatric Annals. 1980;9(4):154-62.
  5. Suknuntha K, Yu Q, Weisman PS, Corliss RF. Fatal adrenal crisis due to Addison's disease arising in the context of autoimmune polyglandular syndrome type 1. Forensic Sci Med Pathol. 2020;16(1):166-70.
  6. Navarrete-Tapia U. Síndrome poliglandular autoinmune. Rev Med Hosp Gen Méx. 2013;76(3):143-52.
  7. Zhao B, Chang L, Fu H, Sun G, Yang W. The role of autoimmune regulator (AIRE) in peripheral tolerance. J Immunol Res. 2018;2018:3930750.
  8. Sajjadi-Jazi SM, Soltani A, Enayati S, Kakavand Hamidi A, Amoli MM. Autoimmune polyglandular syndrome type 1: A case report. BMC Med Genet. 2019;20(1):1-7.
  9. Manso J, Censi S, Iacobone M, Galuppini F, Pennelli G, Betterle C, et al. First proof of association between autoimmune polyglandular syndrome and multiple endocrine neoplasia in humans. Endocr J. 2020;67(9):929-34.
  10. Resende E, Gόmez GN, Nascimento M, Loidi L, Saborido Fiaño R, Cabanas Rodrίguez P, et al. Precocious presentation of autoimmune polyglandularsyndrome type 2 associated with an AIRE mutation. Hormones (Athens). 2015;14(2):312-6.
  11. Kraus AU, Penna-Martinez M, Shoghi F, Meyer G, Badenhoop K. Monocytic cytokines in autoimmune polyglandular syndrome type 2 are modulated by vitamin D and HLA-DQ. Front Immunol. 2020;11:583709.
  12. Solis Cartas U, García Gónzalez V, Hernández Yane A. Síndrome poliglandular tipo III. A propósito de un caso. Rev Cuba Reumatol. 2014;16(3 Suppl. 1):400-3.
  13. Kahaly GJ, Frommer L. Autoimmune polyglandular diseases. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101344.
  14. Michels AW, Gottlieb PA. Autoimmune polyglandular syndromes. Nat Rev Endocrinol. 2010;6(5):270-7.
  15. Eisenbarth GS. Autoimmune polyendocrine syndromes. Adv Exp Med Biol. 2004;552:204-18.
  16. Lakhotia M, Pahadia HR, Kumar H, Singh J, Tak S. A case of autoimmune polyglandular syndrome (APS) type II with hypothyroidism, hypoadrenalism, and celiac disease – A rare combination. J Clin Diagn Res. 2015;9(4):OD01-3.
  17. Perniola R, Fierabracci A, Falorni A. Autoimmune Addison's disease as part of the autoimmune polyglandular syndrome type 1: Historical overview and current evidence. Front Immunol. 2021;12:606860
  18. Instituto Nacional de Estadística y Geografía. https://cuentame.inegi.org.mx/ monografias/informacion/mex/poblacion/
  19. Singh G, Jialal I. Polyglandular autoimmune syndrome type II. [Updated 2022 Jun 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK525992/

Authors' information:

Luis Edgar Concepción Carrillo
MD Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, Mexico
ORCID ID: 0000-0002-2195-022X
E-mail: luisedgarcoca@gmail.com

Miriam Deyanira Rodríguez Piña
MD Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, Mexico
ORCID ID: 0000-0003-1882-2814
E-mail: miriam_drp@hotmail.com

Mariana Guadalupe Pineda González
MD Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, Mexico
ORCID ID: 0000-0003-1013-9500
E-mail: mariana.pineda2910@gmail.com

Fátima García Ocampo
MD Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, Mexico
ORCID ID: 0000-0002-7034-8673
E-mail: faty.2000.14@gmail.com

Hugo Mendieta Zerón
PhD Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, Mexico, and Maternal-Perinatal Hospital «Mónica Pretelini Sáenz»
ORCID ID: 0000-0003-3492-8950
E-mail: hmendietaz@gmail.com

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from companies manufacturing medications and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Hugo Mendieta Zerón
PhD Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, Mexico, and Maternal-Perinatal Hospital «Mónica Pretelini Sáenz»

Paseo Tollocan Poniente 201, Universidad, 50010, Toluca, Mexico

E-mail: hmendietaz@gmail.com

Materials on the topic:
  1. EPIDEMIOLOGY OF PRIMARY HYPERPARATHYROIDISM
  2. DIAGNOSTIC AND TACTICAL ERRORS IN THE MANAGEMENT OF PATIENTS WITH PHEOCROMOCYTOMA
  3. BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH TYPE 2 diabetes mellitus in THE HIGH FERTILITY REGION
  4. SOME ASPECTS OF METABOLIC CHANGES IN HYPERPROLACTINEMIA OF TUMOUR AND NON-TUMOUR GENESIS

◄ Back to the list